Breaking News Instant updates and real-time market news.

VIVE

Viveve

$0.39

0.008 (2.09%)

11:22
07/11/19
07/11
11:22
07/11/19
11:22

Viveve checks suggest SUI trial endpoint will be hit, says Stifel

Stifel analyst Jonathan Block said in a note issued last night that his checks with 21 current North American Viveve practices lead him to believe there is a "high likelihood" that the primary endpoint for the company's LIBERATE-International stress urinary incontinence, SUI, trial will be hit. If he is correct, he thinks it would be a catalyst for the shares, though he noted that "several challenges would still remain," including balance sheet concerns. Block keeps a Buy rating and $3 price target on Viveve shares, which are up 6c, or 15%, to 45c in morning trading.

VIVE Viveve
$0.39

0.008 (2.09%)

07/30/18
CHLM
07/30/18
NO CHANGE
CHLM
Hold
FDA warning to off-label competitors positive for Viveve, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt noted that the FDA published seven "Letters to Industry" that were sent to companies that may be violating the law for inappropriately marketing their energy-based devices for vaginal "rejuvenation," but noted that Viveve (VIVE) was not amongst them. He views this as a positive for Viveve, as it signals that the FDA is cracking down on the off-label promotion that he thinks has been a key commercial challenge for the company. Viveve is the only one in the space currently performing a trial for sexual function, placing it "miles ahead of the competition" in terms of obtaining an actual label, added Hewitt, who keeps a Hold rating on the stock due to concerns over the company's operating cash flow burn and uncertainty about financials. The Fly notes that Cynosure, a unit of Hologic (HOLX), was among the companies to receive an FDA warning.
07/31/18
MZHO
07/31/18
NO CHANGE
Target $4
MZHO
Buy
Seven Viveve competitors get FDA warning letters, says Mizuho
The FDA issued a warning letter to seven competitors of Viveve Medical related to the inappropriate marketing of energy-based devices for the treatment of vaginal rejuvenation, Mizuho analyst Difei Yang tells investors in a research note. The analyst anticipates the competitors will likely stop marketing their devices "off label" in the near term. Since Viveve has not received a letter, Yang sees the development as a positive for the company. The letters to competitors will likely provide an opportunity to compete on equal footing with more established players, especially considering Viveve has received two investigational device exemptions from the FDA to conduct clinical trials in both sexual function and stress urinary incontinence, Yang tells investors in a research note. She reiterates a Buy rating on Viveve shares with a $4 price target.
12/07/18
LTCO
12/07/18
NO CHANGE
Target $8.5
LTCO
Buy
Viveve data supports ongoing clinical activity in SUI, says Ladenburg
After Viveve announced 12-month data from its stress urinary incontinence, or SUI, study, Ladenburg analyst Jeffrey Cohen said he believe this data supports ongoing clinical activity and provides additional support for the LIBERATE International and LIBERATE U.S. studies. He reiterates his Buy rating and $8.50 price target on Viveve shares.
01/02/19
STFL
01/02/19
NO CHANGE
Target $19
STFL
Buy
Sientra added to Select List, IntriCon removed at Stifel
Stifel analyst Jonathan Block added Sientra (SIEN) to the firm's Select List, replacing IntriCon (IIN). His survey of 70 dermatologists, 48 plastic surgeons and 25 other doctors "paints a bullish picture" for adoption of Sientra's miraDry over the next 12-24 months, Block tells investors. The overall shift to non-invasive procedures is expected to continue and it appears that miraDry will play a central role, Block added. He keeps a Buy rating on Sientra shares, though he lowered his price target on the stock to $19 from $24. He also cut his price target on Cutera (CUTR) to $17 from $29 and lowered his price target on Viveve (VIVE) to $3 from $5 following his survey work. Block keeps a Hold rating on Cutera and Buy rating on Viveve.

TODAY'S FREE FLY STORIES

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/19/19
07/19
16:20
07/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCBP

BCB Bancorp

$12.71

-0.09 (-0.70%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Earnings
BCB Bancorp reports Q2 EPS 30c, consensus 30c »

Net interest margin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNXM

CNX Midstream Partners

$14.30

-0.205 (-1.41%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Hot Stocks
CNX Midstream Partners raises quarterly distribution 3.6% to 38.65c per unit »

CNX Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$7.25

0.22 (3.13%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Syndicate
Breaking Syndicate news story on Tellurian »

Tellurian files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
07/19/19
07/19
16:15
07/19/19
16:15
General news
Breaking General news story  »

Boston Federal Reserve…

ROKU

Roku

$106.83

-2.18 (-2.00%)

16:13
07/19/19
07/19
16:13
07/19/19
16:13
Conference/Events
Roku management to meet with Oppenheimer »

Bull/Bear Luncheon to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 07

    Aug

EHTH

eHealth

$86.91

-0.59 (-0.67%)

16:12
07/19/19
07/19
16:12
07/19/19
16:12
Initiation
eHealth initiated  »

eHealth initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 14

    Aug

JEF

Jefferies Financial Group

$20.95

-0.13 (-0.62%)

16:11
07/19/19
07/19
16:11
07/19/19
16:11
Conference/Events
Jefferies Financial Group management to meet with Oppenheimer »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

XXII

22nd Century

$1.94

0.04 (2.11%)

16:10
07/19/19
07/19
16:10
07/19/19
16:10
Hot Stocks
22nd Century: FDA accepts, files MRTP application for VLN cigarettes »

22nd Century announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOI

Solaris Oilfield

$13.12

(0.00%)

16:10
07/19/19
07/19
16:10
07/19/19
16:10
Earnings
Solaris Oilfield reports preliminary Q2 revenue $63M-$65M, consensus $58.04M »

"Our second quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Aug

CCNE

CNB Financial

$26.76

0.12 (0.45%)

16:05
07/19/19
07/19
16:05
07/19/19
16:05
Earnings
CNB Financial reports Q2 EPS 64c, two estimates 58c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.81

-0.0999 (-10.98%)

16:05
07/19/19
07/19
16:05
07/19/19
16:05
Hot Stocks
Caxton Corp reports 5.3% passive stake in Sunesis »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRI

Herc Holdings

$40.28

-0.62 (-1.52%)

16:04
07/19/19
07/19
16:04
07/19/19
16:04
Hot Stocks
Gabelli reports 18.15% stake in Herc Holdings »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GMAB

Genmab

$18.08

-0.12 (-0.66%)

15:55
07/19/19
07/19
15:55
07/19/19
15:55
Hot Stocks
Genmab discloses BlackRock stake in company reached 5% »

Genmab A/S announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

DISH

Dish

$40.69

-0.13 (-0.32%)

15:45
07/19/19
07/19
15:45
07/19/19
15:45
Options
Dish call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$19.04

0.5 (2.70%)

15:35
07/19/19
07/19
15:35
07/19/19
15:35
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

15:35
07/19/19
07/19
15:35
07/19/19
15:35
General news
Action Economics Survey results: »

Action Economics Survey…

15:35
07/19/19
07/19
15:35
07/19/19
15:35
General news
Treasury Market Outlook »

Treasury Market Outlook:…

JCP

J.C. Penney

$0.90

-0.175 (-16.28%)

15:32
07/19/19
07/19
15:32
07/19/19
15:32
Hot Stocks
J.C. Penney says has not hired advisors for in-court restructuring, bankruptcy »

J. C. Penney has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.